Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Total Current Liabilities (2016 - 2025)

Cumberland Pharmaceuticals (CPIX) has disclosed Total Current Liabilities for 16 consecutive years, with $36.7 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 16.2% to $36.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $36.7 million through Dec 2025, up 16.2% year-over-year, with the annual reading at $36.7 million for FY2025, 16.2% up from the prior year.
  • Total Current Liabilities hit $36.7 million in Q4 2025 for Cumberland Pharmaceuticals, up from $24.3 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $36.7 million in Q4 2025 to a low of $17.9 million in Q3 2021.
  • Historically, Total Current Liabilities has averaged $25.7 million across 5 years, with a median of $25.4 million in 2022.
  • Biggest five-year swings in Total Current Liabilities: fell 25.03% in 2021 and later surged 48.24% in 2022.
  • Year by year, Total Current Liabilities stood at $19.3 million in 2021, then soared by 48.24% to $28.6 million in 2022, then dropped by 2.09% to $28.0 million in 2023, then rose by 13.01% to $31.6 million in 2024, then grew by 16.2% to $36.7 million in 2025.
  • Business Quant data shows Total Current Liabilities for CPIX at $36.7 million in Q4 2025, $24.3 million in Q3 2025, and $24.0 million in Q2 2025.